| Theme | New perspectives in the management of patients with diabetes undergoing dialysis | |
|---|---|---|
| Title | Medications for glycemic control in patients with diabetes undergoing hemodialysis | |
| Publish Date | 2019/01 | |
| Author | Katsuhito Mori | Department of Nephrology, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine |
| Author | Masaaki Inaba | Department of Nephrology, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine / Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine |
| [ Summary ] | Patients with diabetes undergoing hemodialysis (HD) are susceptible to hypoglycemia secondary to renal insufficiency, physiologically and pharmacologically. Additionally, glycemic disarrays including HD-induced hypoglycemia and hyperglycemia are known to occur. Therefore, achieving appropriate glycemic control in these patients is challenging. The emergence of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that stimulate glucose-dependent insulin secretion has revolutionized the clinical changes in this field. Specifically, DPP-4 inhibitors are widely used owing to the ease of oral administration. Although GLP-1 RAs are injectable formulations, the recent availability of once-weekly GLP-1 RA preparations has led to their wider application in clinical settings. It is expected that these new medications will improve the prognosis in patients with diabetes undergoing HD. | |